Pharmacological Approach for Prevention of Bleomycin-Induced Lung Injury Article Swipe
Mohammad Ayoubifar
,
Farshad Abedi
,
Mohammad Moeini Nodeh
,
Omid Arasteh
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.18502/jpc.v11i1.12638
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.18502/jpc.v11i1.12638
Bleomycin is a chemotherapeutic medication commonly use in the treatment of Hodgkin's disease and germ cell tumors. Pulmonary fibrosis is major and dose limiting adverse effect of the drug. There is not currently any equal alternative approach or a medical agent for prevention of its pulmonary injury. We searched scientific databases in order to find investigational pharmacologic medicines in prevention of bleomycin-induced lung toxicity (BILI). Results revealed that some anti-inflammatory and antioxidant preparations such as statins, N-acetylcysteine (NAC), supplements (vitamin D3, L-arginine, selenium), and renin-angiotensin-aldosterone system (RASS) inhibitors might be effective in preclinical models of pulmonary toxicity mediated by bleomycin. However, we still need more in vivo studies and large human randomized clinical trials to confirm their benefits.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.18502/jpc.v11i1.12638
- OA Status
- diamond
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4382749489
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4382749489Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.18502/jpc.v11i1.12638Digital Object Identifier
- Title
-
Pharmacological Approach for Prevention of Bleomycin-Induced Lung InjuryWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-05-03Full publication date if available
- Authors
-
Mohammad Ayoubifar, Farshad Abedi, Mohammad Moeini Nodeh, Omid ArastehList of authors in order
- Landing page
-
https://doi.org/10.18502/jpc.v11i1.12638Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.18502/jpc.v11i1.12638Direct OA link when available
- Concepts
-
Bleomycin, Medicine, Pharmacology, Pulmonary toxicity, Adverse effect, Pulmonary fibrosis, Lung, Toxicity, Clinical trial, In vivo, Internal medicine, Chemotherapy, Biology, BiotechnologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4382749489 |
|---|---|
| doi | https://doi.org/10.18502/jpc.v11i1.12638 |
| ids.doi | https://doi.org/10.18502/jpc.v11i1.12638 |
| ids.openalex | https://openalex.org/W4382749489 |
| fwci | 0.0 |
| type | article |
| title | Pharmacological Approach for Prevention of Bleomycin-Induced Lung Injury |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10870 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.998199999332428 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis |
| topics[1].id | https://openalex.org/T10417 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9976000189781189 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2740 |
| topics[1].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[1].display_name | Lung Cancer Treatments and Mutations |
| topics[2].id | https://openalex.org/T11900 |
| topics[2].field.id | https://openalex.org/fields/11 |
| topics[2].field.display_name | Agricultural and Biological Sciences |
| topics[2].score | 0.9965999722480774 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1105 |
| topics[2].subfield.display_name | Ecology, Evolution, Behavior and Systematics |
| topics[2].display_name | Fungal Plant Pathogen Control |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776232574 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9212461709976196 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q415571 |
| concepts[0].display_name | Bleomycin |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.8048340678215027 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C98274493 |
| concepts[2].level | 1 |
| concepts[2].score | 0.5951865315437317 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[2].display_name | Pharmacology |
| concepts[3].id | https://openalex.org/C2781047374 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5511351823806763 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2100012 |
| concepts[3].display_name | Pulmonary toxicity |
| concepts[4].id | https://openalex.org/C197934379 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5123556852340698 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[4].display_name | Adverse effect |
| concepts[5].id | https://openalex.org/C2781244666 |
| concepts[5].level | 3 |
| concepts[5].score | 0.49064579606056213 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q32446 |
| concepts[5].display_name | Pulmonary fibrosis |
| concepts[6].id | https://openalex.org/C2777714996 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4707168936729431 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7886 |
| concepts[6].display_name | Lung |
| concepts[7].id | https://openalex.org/C29730261 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4524874985218048 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q274160 |
| concepts[7].display_name | Toxicity |
| concepts[8].id | https://openalex.org/C535046627 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4310246706008911 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[8].display_name | Clinical trial |
| concepts[9].id | https://openalex.org/C207001950 |
| concepts[9].level | 2 |
| concepts[9].score | 0.41764187812805176 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q141124 |
| concepts[9].display_name | In vivo |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.25095582008361816 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| concepts[11].id | https://openalex.org/C2776694085 |
| concepts[11].level | 2 |
| concepts[11].score | 0.17941752076148987 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[11].display_name | Chemotherapy |
| concepts[12].id | https://openalex.org/C86803240 |
| concepts[12].level | 0 |
| concepts[12].score | 0.077625572681427 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[12].display_name | Biology |
| concepts[13].id | https://openalex.org/C150903083 |
| concepts[13].level | 1 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7108 |
| concepts[13].display_name | Biotechnology |
| keywords[0].id | https://openalex.org/keywords/bleomycin |
| keywords[0].score | 0.9212461709976196 |
| keywords[0].display_name | Bleomycin |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.8048340678215027 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/pharmacology |
| keywords[2].score | 0.5951865315437317 |
| keywords[2].display_name | Pharmacology |
| keywords[3].id | https://openalex.org/keywords/pulmonary-toxicity |
| keywords[3].score | 0.5511351823806763 |
| keywords[3].display_name | Pulmonary toxicity |
| keywords[4].id | https://openalex.org/keywords/adverse-effect |
| keywords[4].score | 0.5123556852340698 |
| keywords[4].display_name | Adverse effect |
| keywords[5].id | https://openalex.org/keywords/pulmonary-fibrosis |
| keywords[5].score | 0.49064579606056213 |
| keywords[5].display_name | Pulmonary fibrosis |
| keywords[6].id | https://openalex.org/keywords/lung |
| keywords[6].score | 0.4707168936729431 |
| keywords[6].display_name | Lung |
| keywords[7].id | https://openalex.org/keywords/toxicity |
| keywords[7].score | 0.4524874985218048 |
| keywords[7].display_name | Toxicity |
| keywords[8].id | https://openalex.org/keywords/clinical-trial |
| keywords[8].score | 0.4310246706008911 |
| keywords[8].display_name | Clinical trial |
| keywords[9].id | https://openalex.org/keywords/in-vivo |
| keywords[9].score | 0.41764187812805176 |
| keywords[9].display_name | In vivo |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.25095582008361816 |
| keywords[10].display_name | Internal medicine |
| keywords[11].id | https://openalex.org/keywords/chemotherapy |
| keywords[11].score | 0.17941752076148987 |
| keywords[11].display_name | Chemotherapy |
| keywords[12].id | https://openalex.org/keywords/biology |
| keywords[12].score | 0.077625572681427 |
| keywords[12].display_name | Biology |
| language | en |
| locations[0].id | doi:10.18502/jpc.v11i1.12638 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210195556 |
| locations[0].source.issn | 2322-4509, 2322-4630 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2322-4509 |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Journal of Pharmaceutical Care |
| locations[0].source.host_organization | https://openalex.org/P4310319012 |
| locations[0].source.host_organization_name | Research Center for Rational Use of Drugs (RCRUD) |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319012 |
| locations[0].source.host_organization_lineage_names | Research Center for Rational Use of Drugs (RCRUD) |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Pharmaceutical Care |
| locations[0].landing_page_url | https://doi.org/10.18502/jpc.v11i1.12638 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5092371497 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Mohammad Ayoubifar |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Mohammad Ayoubifar |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5016756874 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-7133-820X |
| authorships[1].author.display_name | Farshad Abedi |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Farshad Abedi |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5004383580 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-3713-7671 |
| authorships[2].author.display_name | Mohammad Moeini Nodeh |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Mohammad Moeini Nodeh |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5005755412 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-8905-1781 |
| authorships[3].author.display_name | Omid Arasteh |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Omid Arasteh |
| authorships[3].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.18502/jpc.v11i1.12638 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Pharmacological Approach for Prevention of Bleomycin-Induced Lung Injury |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10870 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.998199999332428 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis |
| related_works | https://openalex.org/W1993923998, https://openalex.org/W2111404861, https://openalex.org/W2365811023, https://openalex.org/W2102239057, https://openalex.org/W2383309780, https://openalex.org/W4242306840, https://openalex.org/W2121729413, https://openalex.org/W307228711, https://openalex.org/W346282313, https://openalex.org/W80422583 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.18502/jpc.v11i1.12638 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210195556 |
| best_oa_location.source.issn | 2322-4509, 2322-4630 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2322-4509 |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Journal of Pharmaceutical Care |
| best_oa_location.source.host_organization | https://openalex.org/P4310319012 |
| best_oa_location.source.host_organization_name | Research Center for Rational Use of Drugs (RCRUD) |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319012 |
| best_oa_location.source.host_organization_lineage_names | Research Center for Rational Use of Drugs (RCRUD) |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Pharmaceutical Care |
| best_oa_location.landing_page_url | https://doi.org/10.18502/jpc.v11i1.12638 |
| primary_location.id | doi:10.18502/jpc.v11i1.12638 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210195556 |
| primary_location.source.issn | 2322-4509, 2322-4630 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2322-4509 |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Journal of Pharmaceutical Care |
| primary_location.source.host_organization | https://openalex.org/P4310319012 |
| primary_location.source.host_organization_name | Research Center for Rational Use of Drugs (RCRUD) |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319012 |
| primary_location.source.host_organization_lineage_names | Research Center for Rational Use of Drugs (RCRUD) |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Pharmaceutical Care |
| primary_location.landing_page_url | https://doi.org/10.18502/jpc.v11i1.12638 |
| publication_date | 2023-05-03 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 2, 38 |
| abstract_inverted_index.We | 47 |
| abstract_inverted_index.as | 74 |
| abstract_inverted_index.be | 89 |
| abstract_inverted_index.by | 98 |
| abstract_inverted_index.in | 7, 51, 58, 91, 105 |
| abstract_inverted_index.is | 1, 19, 30 |
| abstract_inverted_index.of | 10, 26, 43, 60, 94 |
| abstract_inverted_index.or | 37 |
| abstract_inverted_index.to | 53, 114 |
| abstract_inverted_index.we | 101 |
| abstract_inverted_index.D3, | 80 |
| abstract_inverted_index.and | 13, 21, 70, 83, 108 |
| abstract_inverted_index.any | 33 |
| abstract_inverted_index.for | 41 |
| abstract_inverted_index.its | 44 |
| abstract_inverted_index.not | 31 |
| abstract_inverted_index.the | 8, 27 |
| abstract_inverted_index.use | 6 |
| abstract_inverted_index.cell | 15 |
| abstract_inverted_index.dose | 22 |
| abstract_inverted_index.find | 54 |
| abstract_inverted_index.germ | 14 |
| abstract_inverted_index.lung | 62 |
| abstract_inverted_index.more | 104 |
| abstract_inverted_index.need | 103 |
| abstract_inverted_index.some | 68 |
| abstract_inverted_index.such | 73 |
| abstract_inverted_index.that | 67 |
| abstract_inverted_index.vivo | 106 |
| abstract_inverted_index.There | 29 |
| abstract_inverted_index.agent | 40 |
| abstract_inverted_index.drug. | 28 |
| abstract_inverted_index.equal | 34 |
| abstract_inverted_index.human | 110 |
| abstract_inverted_index.large | 109 |
| abstract_inverted_index.major | 20 |
| abstract_inverted_index.might | 88 |
| abstract_inverted_index.order | 52 |
| abstract_inverted_index.still | 102 |
| abstract_inverted_index.their | 116 |
| abstract_inverted_index.(NAC), | 77 |
| abstract_inverted_index.(RASS) | 86 |
| abstract_inverted_index.effect | 25 |
| abstract_inverted_index.models | 93 |
| abstract_inverted_index.system | 85 |
| abstract_inverted_index.trials | 113 |
| abstract_inverted_index.(BILI). | 64 |
| abstract_inverted_index.Results | 65 |
| abstract_inverted_index.adverse | 24 |
| abstract_inverted_index.confirm | 115 |
| abstract_inverted_index.disease | 12 |
| abstract_inverted_index.injury. | 46 |
| abstract_inverted_index.medical | 39 |
| abstract_inverted_index.studies | 107 |
| abstract_inverted_index.tumors. | 16 |
| abstract_inverted_index.(vitamin | 79 |
| abstract_inverted_index.However, | 100 |
| abstract_inverted_index.approach | 36 |
| abstract_inverted_index.clinical | 112 |
| abstract_inverted_index.commonly | 5 |
| abstract_inverted_index.fibrosis | 18 |
| abstract_inverted_index.limiting | 23 |
| abstract_inverted_index.mediated | 97 |
| abstract_inverted_index.revealed | 66 |
| abstract_inverted_index.searched | 48 |
| abstract_inverted_index.statins, | 75 |
| abstract_inverted_index.toxicity | 63, 96 |
| abstract_inverted_index.Bleomycin | 0 |
| abstract_inverted_index.Hodgkin's | 11 |
| abstract_inverted_index.Pulmonary | 17 |
| abstract_inverted_index.benefits. | 117 |
| abstract_inverted_index.currently | 32 |
| abstract_inverted_index.databases | 50 |
| abstract_inverted_index.effective | 90 |
| abstract_inverted_index.medicines | 57 |
| abstract_inverted_index.pulmonary | 45, 95 |
| abstract_inverted_index.treatment | 9 |
| abstract_inverted_index.bleomycin. | 99 |
| abstract_inverted_index.inhibitors | 87 |
| abstract_inverted_index.medication | 4 |
| abstract_inverted_index.prevention | 42, 59 |
| abstract_inverted_index.randomized | 111 |
| abstract_inverted_index.scientific | 49 |
| abstract_inverted_index.selenium), | 82 |
| abstract_inverted_index.L-arginine, | 81 |
| abstract_inverted_index.alternative | 35 |
| abstract_inverted_index.antioxidant | 71 |
| abstract_inverted_index.preclinical | 92 |
| abstract_inverted_index.supplements | 78 |
| abstract_inverted_index.preparations | 72 |
| abstract_inverted_index.pharmacologic | 56 |
| abstract_inverted_index.investigational | 55 |
| abstract_inverted_index.N-acetylcysteine | 76 |
| abstract_inverted_index.chemotherapeutic | 3 |
| abstract_inverted_index.anti-inflammatory | 69 |
| abstract_inverted_index.bleomycin-induced | 61 |
| abstract_inverted_index.renin-angiotensin-aldosterone | 84 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 4 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.29031982 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |